GMED · Globus Medical Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Globus Medical delivered Q2 2026 sales of $789.6M (+5.9% reported), with U.S. spine up 7% and international spine up 14%, while reaffirming full-year revenue guidance at $3.18B-$3.22B and raising non-GAAP EPS guidance to $4.95-$5.05 from $4.70-$4.80.
- + Q2 revenue grew 5.9% to $789.6M with non-Nevro base business up 9%, led by U.S. spine (+7%) and international spine (+14% as reported)
- + Non-GAAP diluted EPS rose 55.8% to $1.34 and adjusted EBITDA margin expanded 740 bps to 35.4%
- + Raised full-year 2026 non-GAAP EPS guidance to $4.95-$5.05 from $4.70-$4.80, implying 24.4%-26.9% growth over 2025
- + Adjusted gross margin expanded 200 bps to 69.4%, marking seventh consecutive quarter of expansion
- + Deployed $136.1M to repurchase 1.6M shares, with $253.9M remaining under authorization
- − Enabling Technologies revenue declined 25.8% to $26.1M due to shift toward flexible capital acquisition models
- − GAAP diluted EPS declined 26.2% to $1.10 and GAAP net income fell 25.3% to $151.6M, primarily due to prior-year bargain purchase gain
- − Full-year 2026 revenue guidance was reaffirmed rather than raised despite Q2 beat
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 525.14M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA as a percentage of net sales non-GAAP | 33.9% | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Profit non-GAAP | 1.07B | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Profit % of Net Sales non-GAAP | 69.3% | Six Months Ended June 30, 2026 | — |
| Constant Currency Net Sales Growth non-GAAP | 14.5% | Six Months Ended June 30, 2026 | — |
| Free cash flow non-GAAP | 339.32M | Six Months Ended June 30, 2026 | — |
| Non-GAAP diluted earnings per share non-GAAP | $2.46 | Six Months Ended June 30, 2026 | — |
| Non-GAAP net income non-GAAP | 339.19M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GMED
this stock
Globus Medical Inc
|
$10.01B | -13.3% | +16.7% | 19.2 | 5.0% |
|
ABT
Abbott Laboratories
|
$174.90B | -19.4% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -9.3% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -20.7% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.0% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GMED | +0.7% | -7.0% | -17.7% | -7.0% | -13.3% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | +1.9% | -6.6% | -30.7% | -6.6% | -25.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.